~~<i id='79B73152D6'><strike id='79B73152D6'><tt id='79B73152D6'><pre id='79B73152D6'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

author：focus 2025-08-28 08:39:36 - browse：6399

LONDON — GSK said Tuesday it would purchase the asthma-focused drug developer Aiolos Bio for $1 billion upfront, the latest in a string of pharma acquisitions that are bolstering hopes for the industry’s year ahead.

The deal includes up to another $400 million in payments if certain milestones are met.

Aiolos was launched just last year, based in both San Francisco and London. The company, which announced a $245 million Series A round in October, has been readying a Phase 2 trial of its candidate AIO-001 in adult asthma.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： First Opinion Podcast: What happens when kids become caregivers?

focus

entertainment

focus

knowledge

leisure time

Wikipedia

AdobeTherearemanyreasonswhypeoplewriteabouttheloomingthreatofantibioticresistance.Academicsdoittosha

WSS

ADCs take center stage as promising cancer treatments

J&J lung cancer data amount to new salvo against AstraZeneca

Childbirth

Cassava Sciences’ Alzheimer’s clinical trials should be halted

STAT Summit: How researchers deal with rejection

iTeos Therapeutics debuts first data on TIGIT

focus

focus

focus

Cancer drug shortages should be causing more outrage

Is there really a nursing shortage in the U.S.?

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Questions loom on AstraZeneca cancer drug as safety concerns ebb

Moonlake's readout produced a cash windfall. Risks remain

AI used to predict Covid

23andMe had bad news about my health. I wish a person had delivered it

iTeos Therapeutics debuts first data on TIGIT

Heart attack and stroke risk calculators need revising

STAT Readout: Friday, Oct. 20 biotech updates

entertainment

Addiction doctors spar with methadone clinics over legislation

Addiction doctors spar with methadone clinics over legislation

Why a market frenzy over new weight loss drugs defies logic

Dark money group runs ads on China biotech bill

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

Questions loom on AstraZeneca cancer drug as safety concerns ebb

focus

knowledge

leisure time

Wikipedia